Research findings from the Johns Hopkins Kimmel Cancer Center show how higher viscosity, or resistance to flow, of the extracellular fluid that surrounds cells enables cancer cells to migrate more rapidly from a primary tumor to other sites in the body.
Researchers at University of California San Diego School of Medicine and the VA San Diego Healthcare System, with colleagues elsewhere, report that a polygenic hazard score based on 290 genetic variants could be an effective tool for predicting genetic risk of lethal prostate cancer.
Researchers at VCU Massey Cancer Center published study findings that establish rationale for the use of a class of drugs known as MDA-9 inhibitors as a potential treatment option for aggressive liver cancer.
A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center and the University of California San Francisco has discovered the underlying cause of gender differences in treatment-associated myocarditis after immune checkpoint inhibitor treatment. Their findings point to possible treatment strategies for this side effect, which disproportionately affects female patients.
Researchers at UT Southwestern reported in the journal Nature Cancer that Talzenna (talazoparib) successfully shrank the tumors of breast cancer patients with mutations in the PALB2 gene.
In a large analysis of prostate cancer patients treated internationally across 12 randomized trials, research from UCLA Jonsson Comprehensive Cancer Center suggests that it is almost universally optimal for men to receive androgen deprivation therapy during and after radiation therapy, rather than before and during RT.
Researchers from MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival in patients with oligometastatic prostate cancer. Findings from the multicenter EXTEND trial were presented Oct. 25 at the 2022 American Society for Radiation Oncology Annual Meeting.
Through a genomic screening method known as CRISPR/CAS9 screening, Massey scientists—led by Anthony Faber and Jennifer Koblinski—identified a specific enzyme called UBA1 that revealed itself as an ideal therapeutic target in triple negative breast cancer. Using a novel UBA-inhibiting drug called TAK-243, they blocked the cellular function of UBA1 and effectively killed cancer cells in patient-derived breast tumors in mice.
Researchers recently completed the first human trial of proton FLASH radiotherapy at the Cincinnati Children’s/University of Cincinnati Medical Center Proton Therapy Center. FLASH RT was shown to be as safe and appeared to be as effective as conventional radiation without causing unexpected side effects in the study in a small number of people with bone cancer.
An analysis of data on the use of radiation therapy in a large clinical trial of patients with HR+, HER2- breast cancer who had one to three involved lymph nodes and a 21-gene recurrence score of 25 or less found that rates of locoregional recurrence of the disease were low regardless of whether a patient had received regional node irradiation. The results suggest that a randomized clinical trial is required to answer the question of whether these favorable-risk patients can safely skip RNI.